Related Experiment Video
Updated: Jul 14, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
[Relative bioavailability of roxithromycin dispersive tablets in healthy volunteers]
Ting Huang1, Tongling Li, Lan Yang
1West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Abstract:
The relative bioavailability of roxithromycin dispersive tablet in healthy volunteers was evaluated in this study. Its concentration in plasma was detected by high performance liquid chromatography (HPLC) after twenty healthy male volunteers were given each a single dose of 300 mg roxithromycin. The experiment data were obtained using DAS programme. The values of Cmax were 10.16+/-1.46 and 10.34+/-1.66 microg x ml(-1) at 2.33+/-0.61 and 2.28+/-0.62 h respectively; of t1/2 were 9.00+/-1.58 and 8.68+/-1.66 h respectively; of AUC0-->Tn were 143.32 +/-25. 80 and 138.93+/-22. 49 microg x h x ml(-1) respectively; of AUC0-->infinity were 158.63+/-26.86 and 153.77+/-24.75 microg x h x ml(-1) for test and reference drugs. Relative bioavailability of the tested roxithromycin was 103.63%+/-14.04%. The result showed that the two dispersive tablets are bioequivalent.
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Modified-Release Drug Delivery Systems: Bioavailability
Bioavailability Study Design: Absolute Versus Relative Bioavailability
Bioavailability: Overview
Bioavailability: Overview
Bioavailability: Influencing Factors
